Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsy

1 Jan 2018

Abstract excerpt

Abstract: The introduction of druggable targets has significantly improved the outcomes of non-small cell lung cancer patients (NSCLC). EML4-ALK translocation represents 4–6% of the druggable alterations in NSCLC. With the approval of Crizotinib, first discovered drug for the EML4-ALK translocation, on first line treatment for patients with detected mutation meant a complete change on the treatment landscape. The...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Extracellular vesicles in disease
Share to Galectins and Cancer Biology
Share to Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 35117067
DOI: 10.21037/tcr.2018.11.35

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

EML4-ALK translocation identification in RNA exosomal cargo (ExoALK) in NSCLC patients: a novel role for liquid biopsyPMID 35117067Read ↗

Future Perspectives in Detecting EGFR and ALK Gene Alterations in Liquid Biopsies of Patients with NSCLC.Semantic proximity Read ↗

The emerging roles of NGS-based liquid biopsy in non-small cell lung cancerSemantic proximity Read ↗

Exosome-based detection of activating and resistance EGFR mutations from plasma of non-small cell lung cancer patientsSemantic proximity Read ↗

Different Liquid Biopsies for the Management of Non-Small Cell Lung Cancer in the Mutational Oncology Era.Semantic proximity Read ↗

[ALK-Diagnostics in NSCLC - Immunohistochemistry (IHC) and/or Fluorescence-in-situ Hybridisation (FISH)].Semantic proximity Read ↗

Extracellular vesicle-derived DNA for performing EGFR genotyping of NSCLC patients.Semantic proximity Read ↗

Liquid Biopsy for Investigation of Cancer DNA in Esophageal Adenocarcinoma: Cell-Free Plasma DNA and Exosome-Associated DNA.Semantic proximity Read ↗

The Tissue Is the Issue: Personalized Medicine for Non-Small Cell Lung CancerSemantic proximity Read ↗

[Application of liquid biopsy in clinical practice: the importance of a scientific network for effective use of the biomolecular markers in NSCLC patient..]Semantic proximity Read ↗

Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid BiopsySemantic proximity Read ↗

Liquid biopsy for the management of NSCLC patients under osimertinib treatment.Semantic proximity Read ↗

Fusion gene and splice variant analyses in liquid biopsies of lung cancer patientsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.